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Abstract
Bisphosphonates (BPs) are one of the most common medications used in the treatment
of osteoporosis. Rare but serious conditions which have been associated with BP exposure
include atrial fibrillation, esophageal cancer, atypical femoral fractures and osteonecrosis of the
jaw. There are many proposed risk factors for developing bisphosphonate related
osteonecrosis of the jaw (BRONJ).
In the case study presented below, the patient is a 67 year old Caucasian female. She
has a history of breast cancer and is on Arimidex, an aromatase inhibitor (antiestrogen
medication). She is postmenopausal. She has a history of a hip fracture and her DEXA scan
indicates she has osteoporosis. She is being placed on Fosimax which is an oral
bisphosphonate. A review of literature was conducted on bisphosphonate therapy and the
development of BRONJ to see what additional considerations should be made for this patient.
Background
Osteoporosis is a bone condition “characterized by normal bone mineralization but low
bone mass…and disruption of the bony architecture” (Dunphy, Winland-Brown, Porter &
Thomas, 2015, p. 807). Throughout life, bones continue to remodel and rebuild themselves.
Osteoclasts break down bone while osteoblasts build new bone. Typically osteoblasts and
osteoclasts maintain a homeostatic relationship and bone turnover and rebuilding remain
relatively stable. This relationship is influenced by a number of hormones including estrogen.
Estrogen “has been shown to inhibit osteoclastogenesis, induce osteoclast apoptosis, and
decrease erosive activity of osteoclasts” (Dunphy et al., 2015, p. 810). Therefore
postmenopausal women (or women being treated with antiestrogen medications) are at an
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increased risk of developing osteoporosis due to osteoclastic activity outpacing osteoblastic
activity.
Osteoporosis is treated through a variety of lifestyle management treatments,
nutritional supplementation of calcium and Vitamin D, and various medications including
bisphosphonates therapy.
Bisphosphonate Therapy
Bisphosphonate (BP) therapy is the most common pharmacological intervention in the
treatment of osteoporosis. Bisphosphonates reduce the activity of osteoclasts which decreases
the rate of bone resorption and increases the bone density. BPs bind tightly to the surface of
bones. Absorption of oral BPs are around 1% while absorption of IV BPs are higher than 50%.
Bisphosphonates levels decrease rapidly in plasma but may last as long as 10 years in bone
structures (Hasegawa et al., 2013; Sigua-Rodriguez, Da Costa Riberiro, De Brito, Alvarez-Pinzon,
& De Albergaria-Barbosa, 2014).
Oral bisphosphonates are typically well tolerated but do require specific patient
education on administration and potential side effects. Most oral bisphosphonates are
available in daily or weekly formulations. They must be taken on an empty stomach with at
least 8 ounces of water to maximize absorption and decrease the risk of the medication sticking
in the esophagus. The patient must remain in an upright position for a minimum of 30 minutes
after taking the medication to decrease complications of reflux. Oral BPs are contraindicated in
those with esophageal disorders, a history of certain bariatric surgeries, and those unable to
remain upright for 30 minutes following medication administration (Rosen, 2017).
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IV BPs side effects include an increase the risk of hypocalcemia and transient flu-like
symptoms (Rosen, 2017). IV BPs are most commonly used at much higher doses than oral BPs
to treat metastatic cancers (especially breast, lung, and prostate) and multiple myeloma.
Rare but serious conditions which have been associated with BP exposure include atrial
fibrillation, esophageal cancer, atypical femoral fractures and osteonecrosis of the jaw (Suresh,
Pazianas & Abrahamsen, 2014). This paper will focus on bisphosphonate related osteonecrosis
of the jaw (BRONJ).
Case Report
Date: 3/10/2017
Chief Complaint: 8 week post-op recheck for right hip replacement
Subjective
HPI: The patient is a 67 year old Caucasian female who presents today for post-hospitalization
follow-up. Eight weeks ago she fell in the bathtub, developing a right hip fracture which
required total right hip replacement. She reports her incision is healing well. She denies any
redness or signs of infection. She had not had any fevers. She has completed physical therapy
and is able to ambulate without difficulty. She feels she has healed well and has good range of
motion in her hip. Takes 650 mg Tylenol TID for pain which she rates at an average of 3/10
(worst). With medication, her pain is 0/10. Denies any other physical complaints or concerns
at this time.
Past medical history: hypertension, right breast cancer
Surgeries: right hip replacement (2017), right breast lumpectomy
Medications: Lisinopril 10 mg PO daily, Arimidex 1 mg PO daily, Tylenol 650 mg PO TID PRN.
Denies supplements, herbs, homeopathic treatments or other OTC medications.
Allergies: NKDA. No food, environmental or latex allergies.
Social history: She is a retired high school Chemistry teacher. She is widowed and has three
grown children. She is a current smoker of ½-1 pack of cigarettes daily with a 75 year pack
history. Drinks 1-2 alcoholic drinks per month. No current exercise plan but has been walking
daily since her hip replacement. Denies any illegal drug use.
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Family history: Non-contributory.
Screenings/preventive care:
Mammogram – last completed October 2016, negative
Pap smear – unsure when she last had one completed. Reports she has never had abnormal
screen.
Colonoscopy – has not had one
Dexa scan – 5/16/2011
Lung cancer screening – has not had one
Hepatitis C screening – has not had one
Dentist – sees regularly
Eye exam – not addressed
Immunizations:
TD/Tdap – unsure of last date
Influenza – none this season
Pneumovax – has not received
Zostavax – had recently, unsure of date
ROS
Constitutional: Denies fever, chills, night sweats. No recent weight loss.
Chest: No chest pain or palpitations. No shortness of breath. No cough or cold symptoms.
GI/GU: No changes in appetite. No changes in bowel or bladder habits. No dark or tarry stools.
No blood in urine. No urgency or frequency.
MSK: See HPI.
Mental health: Reports her mood has been good.
Objective
Vital signs: see chart
Physical exam
General: Patient is well-groomed. No distress. Answers questions thoroughly. Maintains
bright affect and good eye contact. Cooperative throughout examination.
Lungs: Breathing easy, regular and unlabored. Breath sounds clear through all lung fields, no
wheezes or crackles.
Heart: Regular heart rate and rhythm. S1, S2, no murmur.
Abdomen: Soft, nontender, no organmegaly.
Right hip: Incision healed. No unusual erythema or swelling. No signs of infection. No
tenderness to palpation. Appropriate range of motion.
DEXA scan
Lumbar spine: The total BMD for L1 to L4 is 0.594 g/cm. The BMD is 67% of the young adult
reference population and 69% of the age matched population. The T-score is -4.1.
WHO classification – osteoporosis
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Femoral neck: The total BMD is 0.620 g/cm. The BMD is 73% of the young adult reference
population and 90% of the age matched population. The T-score is -2.1.
Who classification – osteopenia
Comparison: Today’s study is compared with a previous examination dated 5/16/11 and a
baseline examination of 5/18/2010.
Lumbar spine: There has been an interval decrease in lumbar spine BMP of 1.7% when
compared to the baseline examination with an interval increase of 2.9% when compared to the
previous examination.
Hip: There has been an interval increase in hip BMP of 0.2% when compared to the baseline
examination with an interval decrease of 1.0% when compared to the previous examination.
Conclusion:
1. Bone density consistent with osteoporosis.
2. Fracture risk is high.
Recommendations:
1. Adequate vitamin D and calcium.
2. Follow up DEXA scan in 2 years to evaluate for change or response to treatment.
Assessment
1. 8 week right hip replacement post-operative exam
2. Osteoporosis
Plan
Patient presents today for post-op exam following a right hip replacement secondary to falling
in her bathtub and fracturing hip 8 weeks ago. She has successfully completed physical therapy
and has good ROM in her hip. I have encouraged her to continue walking daily. As she feels
her pain is at a manageable level, I have encouraged her to decrease the amount of Tylenol she
is taking daily and discontinue it if possible. She should follow-up with orthopedics as
scheduled.
DEXA scan completed today shows findings consistent with osteoporosis and her BMD has
decreased from baseline and last DEXA scan. Patient will begin vitamin D and calcium
supplements daily. Fosimax 70 mg PO weekly prescribed. Instructions regarding medication
provided. Patient is to call my office if she has any problems tolerating this medication.
Provided counseling on tobacco cessation. Patient is not interested in quitting smoking at this
time.
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Recommended patient schedule well-visit to review needed screenings and general health.
Influenza and Pneumovax will be given today.
Patient in agreement with the above treatment plan. Denies any questions at this time. She
should call or return to the clinic if she has any new or worsening symptoms. Please schedule
well-exam.
Literature Review
In the case study presented, the patient is a 67 year old Caucasian female. She has a
history of breast cancer and is on Arimidex, an aromatase inhibitor (antiestrogen medication).
She is postmenopausal. She has a history of a hip fracture and her DEXA scan indicates she has
osteoporosis. She is being placed on Fosimax which is an oral bisphosphonate. A review of
literature was conducted on oral bisphosphonate therapy and the development of BRONJ to
see what additional considerations should be made for this patient.
Pathophysiology and Diagnosis of BRONJ
While the exact pathophysiology of BRONJ is not fully understood, there are two
proposed theories.
One is the osteoclast-based, “inside-out,” theory, in which inhibition of osteoclastic
activity and marked suppression of bone turnover, together with spread of physiologic
micro-damage and possibly local infection, leads to bone death within the jaw, with
subsequent exposure. As such, the bone exposure is a late event. The second, “outsidein,” theory suggests a break in the oral mucosa leads to ingress of bacteria and local
infection which, coupled with poor bone remodeling, leads to bone death (Lerman et
al., 2013, p. 977).
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Additionally, it is believed that BPs may destroy some of the microvasculature of bone,
causing decreased wound healing (Hasegawa et al., 2013) and there is a reduction of
endothelial derived growth factors (Vaszilko et al., 2014).
The American Society for Bone Mineral Research has developed three criteria for the
diagnosis of BRONJ: “(1) current or previous treatment with bisphosphonate; (2) exposed bone
in the maxillofacial region that has persisted for more than eight weeks; and (3) no history of
radiation therapy to the jaws” (Coskun Benlidayi & Guzel, 2013, p. 1). The American
Association of Oral and Maxillofacial Surgeons (AAOMS) list several risk factors for developing
BRONJ including: drug related risk-factors, duration of therapy, local risk factors, demographic
and systemic risk factors, genetic risk factors, and preventative factors (Coskun Benlidayi &
Guzel, 2013).
Drug Related Risk Factors
Shintani et al. (2015) conducted a study of 59 patients who were treated for BRONJ in
Japan. The aim of their study was to compare the prognosis of patients who received oral BPs
with those treated with IV BPs. All patients discontinued BP therapy when they were diagnosed
with BRONJ. The treatment of BRONJ lesions was based on the severity of the lesion and
followed the guidelines defined by AAOMS.
There were 29 patients in the oral BP group and 30 patients in the IV BP group (although
3 were eventually excluded as they refused treatment for BRONJ). In the oral BP group, 28 of
the patients were being treated for osteoporosis and one for Paget ’s disease. The patients in
the IV BP group were being treated for malignancies including 18 for breast cancer, 6 for
multiple myeloma, 4 for prostate cancer, and 1 each for gastric cancer and hepatocellular
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carcinoma. Each patient was seen monthly for a year after diagnosis and treatment of their
BRONJ lesion.
In the oral BP group, 27 of 29 patents (93%) were fully healed within the year while only
12 of 27 patients (44%) who received IV BPs were fully healed. This indicates that patients who
are on oral BP therapy and develop BRONJ may recover quicker than those who have been
treated with IV BPs.
Duration of Therapy
Barasch et al. (2011) compared 191 patients with osteonecrosis of the jaw (ONJ) with
573 matched control patients (3 for each ONJ patient). Their patients stemmed from 3 areas in
the United States. All forms of ONJ were included although patients with a history of facial
trauma or sickle cell disease were excluded. Data collected included “tooth loss, periodontal
disease, caries, endodontic problems, gingival bleeding, suppuration, pain or sensitivity,
neurosensory disturbances, and information on dental procedures” (p. 440) which occurred in
the 3 years preceding diagnosis of ONJ (or the previous 3 years for the case controlled
matches).
The researchers found that 113 of 191 (83%) of the ONJ patients and 71 of 573 (15%) of
the control patient had been on BP therapy. Median length of use was 5.6 years for the ONJ
patients and 4.2 years for the control cases. “Duration of bisphosphonate use < 2 years was
associated with a ten-fold risk of ONJ, while with duration > 2 years, that risk nearly
quadrupled” (Barasch et al., 2011, p. 441). Additionally, the risk of developing ONJ was higher
in patients treated with IV BPs as compared to oral BPs.
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Local Risk Factors
Pichardo and van Merkesteyn (2013) conducted a study reviewing 45 patients in the
Netherlands diagnosed with BRONJ to determine if a dental origin could be found. Sixteen
patients had received oral BP therapy for a minimum of 24 months each. Twenty-nine patients
had received IV BP therapy for a minimum of 12 months each. The patients were classified into
4 groups based on the cause of their BRONJ lesion: a certain dental focus (recent dental
procedure or pre-existence of periodontal disease at site of lesion), a presumable dental focus
(an elevated mylohyoid ridge or trauma caused by ill-fitting dentures), spontaneous (with no
previous dental history or trauma) and unknown (unclear or untraceable dental history).
In 36 of the 45 cases a certain dental focus was found. In 9 of the 45 cases a presumable
dental focus was found. There were no cases of spontaneous BRONJ. One of the 45 cases was
of unknown origin. They did not find a difference in the origin of BRONJ lesions in those taking
oral BPs compared to those taking IV BPs.
Dental extraction.
Dental extraction has been proposed as a major risk factor of developing ONJ. Following
a tooth extraction, patients have a 5.3 to 53 times higher risk of developing ONJ. However, oral
bacterial infections (such as those stemming from an infected tooth) may also place a patient
on BPs at high risk of developing BRONJ, so extraction of an infected tooth may not be
avoidable (Yamazaki et al., 2012).
Yamazaki et al. (2012) conducted a cohort study to “estimate the cumulative incidence
(of developing ONJ) after tooth extraction in patients with and without administration of BP,
and to identify potential risk factors, including oral status” (p. 1398). They conducted a
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retrospective analysis of 3,216 patients who had tooth extraction surgery at a university
hospital in Japan. Patient information collected included patient demographics, risk factors,
types of BPs administered, and the condition of dental status.
There were 126 patients who had been treated with BPs (86 received oral BPs, 17
received IV BPs). There were 3,090 patients who had no history of BP therapy. Of the 126
patients with a history of BP therapy, 5 (3.9%) developed BRONJ. Only 1 (0.032%) of the 3,090
patients who were BP naïve developed ONJ. “By route of administration, cumulative incidence
was 1.0% among patients treated with oral BP and 14.8% in those treated with intravenous BP
(Yamazaki et al., 2012, p. 1400).
The authors found the major risk factor of ONJ development was BP therapy, especially
when given intravenously. Age alone was not a significant risk factor; however patients over
the age of 65 had a higher rate of IV BP treatment, therefore increasing their risk. Smoking
status, steroid use, chemotherapy, diabetes, and oral health were not statistically significant
risk factors in this study. Poor oral health had been found to be a risk factor in other studies,
but the authors of this study report their patients received oral examinations, screenings, and
oral cleaning which may have decreased the potential complications of poor oral health among
their participants.
Due to the low number of patients who developed ONJ, the authors report it is difficult
to conclusively determine which additional risk factors may lead to developing ONJ lesions.
Dental implants.
Dental implants have also been suggested as a risk factor for developing BRONJ. LópezCedrún et al. (2013) conducted a retrospective study of 9 patients who were treated with oral
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BPs, received dental implants, and developed BRONJ within 3 years. The participants of this
study lived within a 100 kilometer radius of Galicia, Spain. The aim of their study was “to
describe the clinical characteristics of BRONJ associated with dental implants in patients taking
bisphosphonates orally” (López-Cedrún et al., 2013, p. 875). The data variables collected
included:
sex, age, type of bisphosphonate given, indications for and duration of treatment,
coexisting conditions, use of corticosteroids, smoking, number and sites of implants
inserted, number of implants involved in the BRONJ lesion, interval between the
insertion of the implant and the development of BRONJ, clinical presentation of the
lesions, treatment of the lesions, and the clinical course (López-Cedrún et al., 2013, p.
875).
Their study involved 9 patients (8 women, 1 man) who received a total of 57 dental
implants (29 mandibular and 28 maxillary). BRONJ lesions were more commonly found
involving the mandibular implants (present in 8 of the 9 patients), especially in the molar and
premolar areas. Four of the patients developed BRONJ within the first year of receiving dental
implants; the other 5 patients developed BRONJ later than one year.
Due to the limited number of patients in this study, the researchers were unable to
determine which coexisting factors may influence the development of BRONJ.
Demographic and Systemic Risk Factors
Osteoporosis.
Huang et al. (2015) conducted a population-based cohort study in Taiwan containing
two groups who received dental extractions between the years 2000 and 2010. The first group
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contained 19,399 patients who were diagnosed with osteoporosis. The second group
contained 38,669 age and gender matched comparison patients. Patients with a history of
osteonecrosis were excluded from both groups. The goals of this study are “(1) to investigate
the incidence of BRONJ in osteoporotic patients with oral BPs administration, and (2) to
estimate the correlation between BRONJ and BPs usage in patients with osteoporosis” (Huang
et al., 2015, p. 3).
After controlling for age, gender, hypertension, diabetes and cancer; the researchers
found the osteoporosis group developed ONJ at a rate of 11.72 per 10,000 person-years
compared to 5.32 per 10,000 person-years in the non-osteoporosis group. The rate of ONJ
development slightly increased (but not statistically significant) in patients who were treated
with oral BPs and those with mild osteoporosis who did not receive BP treatment as compared
to those without osteoporosis. However, those who had a large cumulative dose of BPs or had
used BPs for many years had a statistically higher rate of developing ONJ than patients without
osteoporosis.
In both cohorts, when the annual frequency of dental extraction increased, the risks of
developing ONJ increased. Both groups had low rates of ONJ with an annual frequency of
dental extraction below two. However, patients who had osteoporosis treated with BPs who
had more than two dental extractions in one year developed ONJ at a rate of 46.6 per 10,000
person-years. Frequent dental extractions may be related to poor dental hygiene and dental
care which may independently raise the risk of ONJ development. Based on their research and
review of literature, the researchers reported that the severity of osteoporosis is a large factor
in the development of ONJ while BPs “play a synergistic role” (Huang et al., 2015, p. 9).
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Estrogen therapy.
Vaszilko et al. (2014) conducted a prospective study involving 93 patients (74 females,
19 males) seen at their clinic in Budapest who were diagnosed with BRONJ. Comorbid diseases
were recorded. Each patient’s ONJ lesion was surgically treated in a similar manner and
recurrence rates were noted. As it is well known that lower levels of estrogen increase
osteoporosis risks, the authors wanted to explore if there is a relationship between
antiestrogen therapy and BRONJ development.
Thirty-seven of the 93 patients in this study had breast cancer with 80% of those
patients having estrogen receptor positive cancer treated with antiestrogen therapy. The
researchers found that patients who had estrogen receptor negative breast cancer developed
recurrent BRONJ at rates similar to other underlying pathologies (such as multiple myeloma or
prostate cancer). However, patients with estrogen positive cancer treated with antiestrogen
therapy developed recurrent BRONJ lesions at a statistically significant higher rate than breast
cancer patients who were not on antiestrogen therapy. This indicates that breast cancer itself
is not a risk factor but rather decreased estrogen levels that may lead to recurrent BRONJ
lesions.
Oral health in postmenopausal women.
Grgić et al. (2017) conducted a non-interventional clinic study of 120 postmenopausal
women treated at a single dental clinic in Serbia. The women were 50 to 70 years old and
postmenopausal. They were divided into three groups. The first group (O) consisted of 45
women diagnoses with osteoporosis and had never been on BP therapy or had been treated
with oral BPs for less than 6 months. The second group (OBP) consisted of 45 women

OSCE CASE STUDY

16

diagnosed with osteoporosis who had been on oral BP therapy for 6 months or more. The
third, control group (C) consisted of 30 women who did not have osteoporosis. Each patient
was examined by the same periodontist and periodontal health was measured using the plaque
index, the gingival index, the bleeding index, clinical attachment loss, pocket depth, and the
DMFT (decayed, missing, and filled teeth) index.
“Our study showed that women who are taking BP therapy had higher gingival index
than C or O group and higher pocket depth than the O group” (Grgić et al., 2017, p. 155). The
OBP group also had an increased bleeding index. However, they did not find significant
differences in the overall stage of periodontal disease between the three groups. The
researchers concluded that oral BP therapy may cause local irritation in the oral cavity, leading
to increased risk of lesion development.
Preventative Factors
There is much debate regarding how BRONJ lesions should be treated. “Specific
management regimens have included chlorhexidine rinses, antibiotic therapy, non-surgical
sequestrectomy, and surgical debridement and/or resection of necrotic bone (Lerman et al,
2013, p. 978). Most organizations recommend conservative management however these
guidelines are based on expert opinion and have not been thoroughly researched.
Two surgical interventions.
Mozzati, Arata, and Gallesio (2013) completed a prospective study comparing two
different surgical tooth extraction procedures on patients who were receiving oral BP therapy
at a single dental center in Italy. All of the patients were currently on BP therapy, had been
taking oral BPs for a minimum of 24 months and had never had irradiation of the maxillofacial
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area or previous dental extractions. “A total of 334 subjects were treated with delicate surgery
and closure by primary intention (Protocol A), while the other 366 were treated with
nontraumatic avulsion and closure by secondary intention (Protocol B)” (p. 1708). All patients
received a radiologic examination preoperatively and one year postoperatively. They also
received professional oral hygiene one week prior to surgery.
There were a total of 700 patients between the two groups and a total of 1,480
extractions completed. None of the patients developed BRONJ or experienced delayed healing.
Based on their results and review of literature, the researchers proposed that BRONJ
development in patients on oral bisphosphonate therapy is a rare complication but good oral
care and minimally traumatic oral surgery may further reduce the risk.
Discontinuing BP therapy prior to dental surgery.
Hasegawa et al. (2013) completed an observational study to determine how
discontinuing oral BP therapy for 3 months prior to tooth extraction affects the development of
BRONJ and wound healing. Their study included 212 Japanese patients (18 males and 183
females), with a total of 434 teeth extracted. The first group (101 patients, 262 teeth)
discontinued BP treatment for 3 months prior to having their extraction surgery. The second
group (111 patients, 172 teeth) continued on BP treatment as it was deemed too risky for them
to discontinue their BP medication or the oral surgery was required sooner than 3 months.
There were no cases of BRONJ development in the group that discontinued BPs prior to
surgery although there were 2 cases which had delayed wound healing following tooth
extraction. They were treated with antibiotics and a mouth rinse. Both cases healed within 12
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weeks. One case of BRONJ developed in the second group, developing an intraoral fistula with
bone exposure. At 120 weeks after tooth extraction, this wound was not yet fully healed.
Based on the results on their study and their review of literature, the authors suggested
discontinuing oral BPs 3 months prior to and 3 months after elective invasive dental surgery
when possible. As BPs remain in bone for several years after discontinuation, they conclude:
Discontinuation of BP therapy for a few months may have little effect on the BP that has
already incorporated into the bone. However, other effects of BP, such as its
antiangiogenic activity and inhibition of proliferation and migration of epithelial cells,
may be reduced, and this may help healing of the overlying mucosa (Hasegawa et al.,
2013, p. 561).
Learning Points
While the body of knowledge regarding BRONJ lesions is vast, consensus regarding the
development, risk factors, and treatment of BRONJ is not fully understood and the available
evidence is contradictory at times. Regarding the studies collected in this review of literature,
several weaknesses are present. Most of the studies enrolled patients in limited geographical
area. Some of the studies contained too few patients to make generalized assumptions
regarding BRONJ. Each of the studies by itself does not provide evidence that is strong enough
to apply to a generalized population but each study adds to the growing body of knowledge
that makes understanding of this condition stronger.
The patient in the case study has several risk factors of developing BRONJ. She has
osteoporosis which has been found to be an independent risk factor (Huang et al., 2015). As
she is starting on oral BP therapy, she needs to be aware that this does increase her risk of
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developing BRONJ but the risk is very small compared to IV therapy (Shintani et al., 2015;
Barasch et al., 2011; Yamazaki et al., 2012). The risk does increase the longer she is on the
medication, with nearly a 4-fold increase after being treated with BPs for longer than 2 years
(Barasch et al., 2011). An expert panel has suggested moderate-risk patients be placed on a
drug holiday after 5 years of BP treatment (Suresh et al., 2013).
The majority of BRONJ lesions are of known dental origin (Pichardo and van Merkesteyn,
2013). Dental extraction and/or dental implants may be a triggering event for the development
of BRONJ (Yamazaki et al., 2012; López-Cedrún et al. 2013). Additionally, oral BPs may cause
local irritation in the mouth which may precipitate BRONJ development (Grgić et al., 2017).
This patient has a history of breast cancer that was estrogen receptor positive. She is on
an antiestrogen medication. Use of this medication can increase the severity of her
osteoporosis and may be an additional risk factor for developing BRONJ (Vaszilko et al., 2014).
This patient should receive regular oral care and cleanings. She should be aware that
she should see a dentist if she develops any oral pain or lesions. If she requires oral surgery, it
is important her provider is aware that she is on oral BP therapy. The provider should consider
discontinuing her BP medication for up to 3 months before and after the surgery if delaying the
surgery will not compromise the patient (Hasegawa et al., 2013).
While the use of oral bisphosphonate therapy does carry a risk, the benefits of the
medication make it an appropriate choice for the patient in the case study. After educating the
patient on the benefits and risks of the medication, if she is in agreement with starting the
medication, the provider should prescribe it immediately. She should be educated on
appropriate dental care and what to do if she develops oral pain or lesions. At each follow-up
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visit, the provider should discuss this medication with the patient to determine if she is
compliant with taking the medication as prescribed and if she is experiencing any side effects.
The provider and patient should collaborate on the plan of care on a yearly basis and determine
if the benefits of this medication continue to outweigh the risks.

OSCE CASE STUDY

21

References
Barasch, A., Cunha-Cruz, J., Curro, F. A., Hujoel, P., Sung, A. H., Vena, D., . . . the CONDOR
Collaborative Group. (2011). Risk factors for osteonecrosis of the jaws: a case-control
study from the CONDOR Dental PBRN. Journal of Dental Research, 90(4), 439-444. doi:
10.1177/0022034510397196
Coskun Benlidayi, I., & Guzel, R. (2013). Oral bisphosphonate related osteonecrosis of the jaw:
a challenging adverse effect. ISRN Rheumatology, 2013, 1-6. doi: 10.1155/2013/215034
Dunphy, L. M., Winland-Brown, J. E., Porter, B. O., & Thomas, D. J. (2015). Primary care: the art
and science of advance practice nursing (4th ed.). Philadelphia, PA: F. A. Davis Company
Grgić, O., Kovačev-Zavišić, B., Veljović, T., Novaković-Paro, J., Maravić, T., & Bajkin, B. (2017).
The influence of bone mineral density and bisphosphonate therapy on the determinants
of oral health and changes on dental panoramic radiographs in postmenopausal women.
Clinical Oral Investigations, 21(1), 151-157. doi: 10.1007/s00784-016-1767-6
Hasegawa, T. R. S., Umeda, M., Komatsubara, H., Kobayashi, M., Shigeta, T., Yoshitomi, I., . . .
Komori, T. (2013). The observational study of delayed wound healing after tooth
extraction in patients receiving oral bisphosphonate therapy. Journal of Cranio-MaxilloFacial Surgery, 41(7), 558-563. doi: 10.1016/j.jcms.2012.11.023
Huang, Y. F., Chang, C. T., Muo, C. H., Tsai, C. H., Shen, Y. F., & Wu, C. Z. (2015). Impact of
bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental
extraction: a population-based cohort study. PLoS One, 10(4), e57926. doi:
10.1371/journal.pone.0057926

OSCE CASE STUDY

22

Lerman, M. A., Xie, W., Treister, N. S., Richardson, P. G., Weller, E. A., & Woo, S. (2013).
Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging
and treatment outcomes. Oral Oncology, 49(9), 977-983. Retrieved from
http://dx.doi.org./10.1016/j.oraloncology.2013.05.012
López-Cedrún, J.L., Sanromán, J.F., García, A., Peñarrocha, M., Feijoo, J.F., Limeres, J., & Diz, P.
(2013). Oral bisphosphonate-related osteonecrosis of the jaws in dental implant
patients: a case series. British Journal of Oral & Maxillofacial Surgery, 51(8), 874-879.
doi: 10.1016/j.bjoms.2013.06.011
Mozzati, M., Arata, V., & Gallesio, G. (2013). Tooth extraction in osteoporotic patients taking
oral bisphosphonates. Osteoporosis International, 24(5), 1707-1712. doi:
10.1007/s00198-012-2239-8
Pichardo, S. E. C., & van Merkesteyn, J. P. R. (2013). Bisphosphonate related osteonecrosis of
the jaws: spontaneous or dental origin? Oral Surgery, Oral Medicine, Oral Pathology
and Oral Radiology, 116(3), 287-292. doi: 10.1016/j.oooo.2013.05.005
Shintani, T., Hayashido, Y., Mukasa, H., Akagi, E., Hoshino, M., Ishida, Y., . . . Okamoto, T.
(2015). Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw
caused by oral and intravenous bisphosphonates. International Journal of Oral and
Maxillofacial Surgery, 44(7), 840-844. doi:
http://dx.doi.org./10.1016/j.ijom.2015.03.013
Rosen, H. (2017). The use of bisphosphonates in postmenopausal women with osteoporosis.
UpToDate. Retrieved from http://www.uptodate.com/contents/the-use-ofbisphosphonates-in-postmenopausal-women-with-osteoporosis

OSCE CASE STUDY

23

Sigua-Rodriguez, E. A., Da Costa Riberiro, R., De Brito, A. C. R. Alvarez-Pinzon, N. & De
Albergaria-Barbosa, J. R. (2014). Bisphosphonate-related osteonecrosis of the jaw: a
review of the literature. International Journal of Dentistry, 2014, 1-5. doi:
10.1155/2014/192320
Suresh, E., Pazianas, M., Abrahamsen, B. (20014). Safety issues with bisphosphonate therapy
for osteoporosis. Rheumatology, 53(1), 19-31. doi: https://doiorg/10.1093/rheumatology/ket236
Vaszilko, M., Kovacs, E., Restar, L., Balla, B., Cseplo, K., Kosa, J., & Lakatos, P. (2014). Potential
significance of antiestrogen therapy in the development of bisphosphonate related
osteonecrosis of the jaw. Journal of Cranio-Maxillo-Facial Surgery, 42(8), 1932-1936.
doi: 10.1016/j.jcms.2014.08.002
Yamazaki, T., Yamori, M., Ishizaki, T., Asai, K., Goto, K., Takahashi, K., . . . Bessho, K. (2012).
Increased incidence of osteonecrosis of the jaw after tooth extraction in patients
treated with bisphosphonates: a cohort study. International Journal of Oral &
Maxillofacial Surgery, 41(11), 1397-1403. Retrieved from
http://dx.doi.org/10.1016/j.ijom.2012.06.020

